Cartesian Therapeutics (RNAC) Shares Outstanding (Weighted Average) (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Shares Outstanding (Weighted Average) data on file, last reported at $26.9 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $26.9 million, up 3.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.9 million (up 3.68% YoY), and the FY2025 annual result was $26.0 million, up 50.34% from the prior year.
• Shares Outstanding (Weighted Average) grew to $26.9 million in Q1 2026 per RNAC's latest filing, from $26.0 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $148.5 million in Q2 2022 and troughed at $1.0 million in Q4 2023.
• A 5-year average of $36.7 million and a median of $21.5 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) tumbled 99.09% in 2022, then soared 1559.94% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $1.0 million in 2022, then retreated by 0.01% to $1.0 million in 2023, then soared by 1559.94% to $17.3 million in 2024, then jumped by 50.34% to $26.0 million in 2025, then increased by 3.4% to $26.9 million in 2026.
• Business Quant data shows RNAC's Shares Outstanding (Weighted Average) at $26.9 million in Q1 2026, $26.0 million in Q4 2025, and $26.0 million in Q3 2025.